ArticleAsian Pacific journal of cancer prevention : APJCP2025
mTOR Levels and Metastasis in Luminal Breast Cancer: Implications for Prognosis and Treatment.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the most common cancer in women, with metastasis being the leading cause of mortality. The PI3K/PTEN/Akt/mTORC1 signaling pathway plays a crucial role in cancer cell proliferation, angiogenesis, and invasion, with mammalian target of rapamycin (mTOR) serving as a key regulator. Activation of mTOR is associated with tumor growth and resistance to therapy in luminal and human epidermal growth factor receptor 2 positive (HER2-positive) BC subtypes. This study aims to explore the relationship between serum mTOR levels and metastasis in luminal, HER2-positive and HER2-negative BC subtypes to assess the potential of mTOR as a predictive biomarker and therapeutic target.
methodsThis preliminary cross-sectional study included BC patients with luminal HER2-positive or HER2-negative subtypes. Serum mTOR levels were measured using a Human ELISA kit. The optimal cut-off point for mTOR was determined using a Receiver Operating Characteristic (ROC) curve analysis. Statistical associations between mTOR levels and metastasis were performed using the Chi-square or Fisher's exact test, and the prevalence ratio (PR) with a 95% confidence interval was calculated.
resultsThe ROC curve demonstrated an AUC of 0.996, with an optimal cut-off point for serum mTOR levels at 13.32 ng/mL, showing 100% sensitivity and 96.4% specificity for predicting metastasis. The mean mTOR level was 58.39±250.91 ng/mL, with 50% exhibiting elevated levels (≥13.32 ng/mL). Notably, mTOR levels were significantly higher in HER2-positive cases (113.59±381.87 ng/mL) compared to HER2-negative cases (17.45±14.83 ng/mL; p=0.040). Elevated mTOR levels were significantly associated with metastasis (p<0.001), with a PR of 0.037 (95% CI: 0.005-0.253).
conclusionsIncreased serum mTOR levels (≥13.32 ng/mL) are significantly linked to the presence of metastasis, particularly in HER2-positive BC. These findings suggest serum mTOR as a promising biomarker for metastasis risk and a potential therapeutic target in luminal BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.